|
KMID : 0360220110520070838
|
|
Journal of the Korean Ophthalmological Society
2011 Volume.52 No. 7 p.838 ~ p.845
|
|
|
Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration with a Predominantly Hemorrhagic Lesion
|
|
Cho Yoon-Jung
Park Sung-Pyo
|
|
|
Abstract
|
|
|
Purpose:To report the efficacy and safety of intravitreal ranibizumab monotherapy in patients with age-related macular degeneration with a predominantly hemorrhagic lesion.
Methods:Nineteen eyes of 19 patients with submacular hemorrhage involving the fovea were treated with intravitreal ranibizumab (0.5 mg/0.05 ml) injections as needed. All patients completed at least 4 months of follow-up. Ophthalmologic examinations, fluorescence angiographic evaluations, optical coherence tomography (OCT) examination, and hemorrhage size were analyzed before the injections, and at 1,2,4,6, and 12 months follow-up.
Results:The average VA and mean central retinal thickness (CRT) before ranibizumab treatment were 0.62 ± 0.39 log MAR and 335.76 ± 111.22 μm, respectively. Additionally, the VA and CRT four months after the initial injections were 0.54 ± 0.43 log MAR and 241.42 ± 107.55 μm, respectively. The mean size of the hemorrhage was significantly reduced from 2.87 ± 2.44 DA (disk areas) at baseline to 0.9 ± 1.28 DA at four month follow up.
Conclusions:Intravitreal injection of ranibizumab is an effective treatment option for patients with age-related macular degeneration with a predominantly hemorrhagic lesion.
|
|
|
KEYWORD
|
|
|
Age-related macular degeneration, Predominantly hemorrhagic lesion, Ranibizumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|